Wednesday - July 9, 2025

LOGIN  |  REGISTER
Terns Pharmaceuticals
Compass Therapeutics

Varex Imaging to Present at the Sidoti Small Cap Virtual Conference

September 11, 2023 | Last Trade: US$8.43 0.05 0.60

SALT LAKE CITY / Sep 11, 2023 / Business Wire / Varex Imaging Corporation (Nasdaq: VREX) announced today that management is scheduled to present at the Sidoti Small Cap Virtual Conference.

Management will participate in a fireside chat presentation on Wednesday, September 20, 2023 at 1:00pm EST. The presentation will be webcast live and may be accessed through the following link: https://sidoti.zoom.us/webinar/register/WN_b584FfbtSOy7pvg9PiEx5g

A replay of the presentation will be available on Varex’s website at www.vareximaging.com/news. The replay will be available for 90 days after the presentation.

About Varex

Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that are key components of X-ray imaging systems. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate Varex’s X-ray sources, digital detectors, connecting devices and imaging software in their systems to detect, diagnose, protect and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,400 people located in North America, Europe, and Asia. For more information visit vareximaging.com.

Astria Therapeutics

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page